Please enable JavaScript to continue using this application.

Compare $CADL vs $FDMT | Chartloom

Compare

$CADL vs $FDMT

Candel Therapeutics Inc · 4D Molecular Therapeutics Inc

CADL

Candel Therapeutics Inc

FDMT

4D Molecular Therapeutics Inc

Compare $CADL vs $FDMT

Comparing Candel Therapeutics Inc and 4D Molecular Therapeutics Inc

CADLCandel Therapeutics Inc

FDMT4D Molecular Therapeutics Inc

CADLCandel Therapeutics Inc

Market cap

$728M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

82.7%

52W performance

57.8%

FCF yield

-7.9%

FDMT4D Molecular Therapeutics Inc

Market cap

$697M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

50.39x

Rev growth (TTM)

278712.1%

YTD performance

82.1%

52W performance

38.0%

FCF yield

-22.4%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

CADL

FDMT

Detailed metrics comparison

CADL

Candel Therapeutics Inc

FDMT

4D Molecular Therapeutics Inc

Market Cap

CADL$728M

FDMT$697M

Enterprise Value

CADL$575M

FDMT$646M

Price

CADL$9.94

FDMT$13.33

P/E Ratio

CADLN/A

FDMTN/A

P/S Ratio

CADL6,281.93x

FDMT7.57x

EV/Sales

CADL5,042.14x

FDMT7.02x

EV/EBITDA

CADL0.00x

FDMT0.00x

P/B Ratio

CADL6.18x

FDMT1.85x

P/FCF Ratio

CADLN/A

FDMTN/A

EV/FCF

CADL-10.02x

FDMT-4.13x

PEG Ratio

CADLN/A

FDMTN/A

Forward P/E (NTM)

CADLN/A

FDMTN/A

Forward P/S (NTM)

CADLN/A

FDMT50.39x

Revenue (TTM)

CADL$0

FDMT$92M

Revenue Growth (YoY)

CADLN/A

FDMT278712.1%

Forward Rev Growth

CADL371.1%

FDMT40.6%

Gross Margin (TTM)

CADL0.0%

FDMT0.0%

Operating Margin (TTM)

CADL0.0%

FDMT0.0%

EBITDA Margin (TTM)

CADL0.0%

FDMT-208.8%

Net Margin (TTM)

CADL0.0%

FDMT-194.7%

FCF Margin (TTM)

CADLN/A

FDMT-169.9%

Net Income (TTM)

CADL$-89M

FDMT$-179M

FCF (TTM)

CADL$-57M

FDMT$-156M

EPS (TTM)

CADL-$1.19

FDMT-$2.55

ROE (TTM)

CADL-8938.0%

FDMT-4133.0%

ROA (TTM)

CADL-5631.0%

FDMT-3590.0%

ROIC (TTM)

CADL-6512.0%

FDMT-4087.0%

Cash

CADL$202M

FDMT$70M

Debt

CADL$48M

FDMT$20M

Net Cash/Debt

CADL$154M

FDMT$51M

Current Ratio (TTM)

CADL16.09x

FDMT8.03x

Quick Ratio (TTM)

CADL15.89x

FDMT7.68x

Debt/Equity (TTM)

CADL0.38x

FDMT0.05x

Debt/Assets (TTM)

CADL0.0%

FDMT0.0%

Interest Coverage (TTM)

CADLN/A

FDMTN/A

Net Debt/EBITDA (TTM)

CADL0.00x

FDMT0.00x

Beta

CADL-0.28

FDMT2.90

52W Performance

CADL57.8%

FDMT38.0%

YTD Performance

CADL82.7%

FDMT82.1%

% from 52W High

CADL-29.0%

FDMT-21.3%

% from 52W Low

CADL128.5%

FDMT91.5%

Asset Turnover (TTM)

CADL0.00x

FDMT0.18x

FCF Yield (TTM)

CADL-7.9%

FDMT-22.4%

Earnings Yield (TTM)

CADL-12.2%

FDMT-25.7%

Dividend Yield (TTM)

CADLN/A

FDMTN/A

Rule of 40

CADL0.0

FDMT278,542.3

EV/GP/RG

CADLN/A

FDMTN/A

Ticker research

View CADL research View FDMT research

Metric	CADL Candel Therapeutics Inc	FDMT 4D Molecular Therapeutics Inc
Market & Valuation
Market Cap	$728M	$697M
Enterprise Value	$575M	$646M
Price	$9.94	$13.33
P/E Ratio	N/A	N/A
P/S Ratio	6,281.93x	7.57x
EV/Sales	5,042.14x	7.02x
EV/EBITDA	0.00x	0.00x
P/B Ratio	6.18x	1.85x
P/FCF Ratio	N/A	N/A
EV/FCF	-10.02x	-4.13x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	50.39x
Revenue & Growth
Revenue (TTM)	$0	$92M
Revenue Growth (YoY)	N/A	278712.1%
Forward Rev Growth	371.1%	40.6%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-208.8%
Net Margin (TTM)	0.0%	-194.7%
FCF Margin (TTM)	N/A	-169.9%
Net Income (TTM)	$-89M	$-179M
FCF (TTM)	$-57M	$-156M
EPS (TTM)	-$1.19	-$2.55
ROE (TTM)	-8938.0%	-4133.0%
ROA (TTM)	-5631.0%	-3590.0%
ROIC (TTM)	-6512.0%	-4087.0%
Financial Health
Cash	$202M	$70M
Debt	$48M	$20M
Net Cash/Debt	$154M	$51M
Current Ratio (TTM)	16.09x	8.03x
Quick Ratio (TTM)	15.89x	7.68x
Debt/Equity (TTM)	0.38x	0.05x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-0.28	2.90
52W Performance	57.8%	38.0%
YTD Performance	82.7%	82.1%
% from 52W High	-29.0%	-21.3%
% from 52W Low	128.5%	91.5%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.18x
FCF Yield (TTM)	-7.9%	-22.4%
Earnings Yield (TTM)	-12.2%	-25.7%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	278,542.3
EV/GP/RG	N/A	N/A
Ticker research	View CADL research	View FDMT research

Valuation

P/S Ratio

FDMT

7.57x

CADL

6,281.93x

EV/FCF

CADL

-10.02x

FDMT

-4.13x

Growth & revenue

Revenue Growth TTM

FDMT

278712.1%

Forward Revenue Growth

CADL

371.1%

FDMT

40.6%

Profitability & performance

Gross Margin

CADL

0.0%

FDMT

0.0%

ROE

FDMT

-4133.0%

CADL

-8938.0%

FCF Yield %

CADL

-7.9%

FDMT

-22.4%

52-Week Performance

CADL

57.8%

FDMT

38.0%

Detailed metrics comparison

CADL

Candel Therapeutics Inc

FDMT

4D Molecular Therapeutics Inc

Market Cap

CADL$728M

FDMT$697M

Enterprise Value

CADL$575M

FDMT$646M

Price

CADL$9.94

FDMT$13.33

P/E Ratio

CADLN/A

FDMTN/A

P/S Ratio

CADL6,281.93x

FDMT7.57x

EV/Sales

CADL5,042.14x

FDMT7.02x

EV/EBITDA

CADL0.00x

FDMT0.00x

P/B Ratio

CADL6.18x

FDMT1.85x

P/FCF Ratio

CADLN/A

FDMTN/A

EV/FCF

CADL-10.02x

FDMT-4.13x

PEG Ratio

CADLN/A

FDMTN/A

Forward P/E (NTM)

CADLN/A

FDMTN/A

Forward P/S (NTM)

CADLN/A

FDMT50.39x

Revenue (TTM)

CADL$0

FDMT$92M

Revenue Growth (YoY)

CADLN/A

FDMT278712.1%

Forward Rev Growth

CADL371.1%

FDMT40.6%

Gross Margin (TTM)

CADL0.0%

FDMT0.0%

Operating Margin (TTM)

CADL0.0%

FDMT0.0%

EBITDA Margin (TTM)

CADL0.0%

FDMT-208.8%

Net Margin (TTM)

CADL0.0%

FDMT-194.7%

FCF Margin (TTM)

CADLN/A

FDMT-169.9%

Net Income (TTM)

CADL$-89M

FDMT$-179M

FCF (TTM)

CADL$-57M

FDMT$-156M

EPS (TTM)

CADL-$1.19

FDMT-$2.55

ROE (TTM)

CADL-8938.0%

FDMT-4133.0%

ROA (TTM)

CADL-5631.0%

FDMT-3590.0%

ROIC (TTM)

CADL-6512.0%

FDMT-4087.0%

Cash

CADL$202M

FDMT$70M

Debt

CADL$48M

FDMT$20M

Net Cash/Debt

CADL$154M

FDMT$51M

Current Ratio (TTM)

CADL16.09x

FDMT8.03x

Quick Ratio (TTM)

CADL15.89x

FDMT7.68x

Debt/Equity (TTM)

CADL0.38x

FDMT0.05x

Debt/Assets (TTM)

CADL0.0%

FDMT0.0%

Interest Coverage (TTM)

CADLN/A

FDMTN/A

Net Debt/EBITDA (TTM)

CADL0.00x

FDMT0.00x

Beta

CADL-0.28

FDMT2.90

52W Performance

CADL57.8%

FDMT38.0%

YTD Performance

CADL82.7%

FDMT82.1%

% from 52W High

CADL-29.0%

FDMT-21.3%

% from 52W Low

CADL128.5%

FDMT91.5%

Asset Turnover (TTM)

CADL0.00x

FDMT0.18x

FCF Yield (TTM)

CADL-7.9%

FDMT-22.4%

Earnings Yield (TTM)

CADL-12.2%

FDMT-25.7%

Dividend Yield (TTM)

CADLN/A

FDMTN/A

Rule of 40

CADL0.0

FDMT278,542.3

EV/GP/RG

CADLN/A

FDMTN/A

Ticker research

View CADL research View FDMT research

Metric	CADL Candel Therapeutics Inc	FDMT 4D Molecular Therapeutics Inc
Market & Valuation
Market Cap	$728M	$697M
Enterprise Value	$575M	$646M
Price	$9.94	$13.33
P/E Ratio	N/A	N/A
P/S Ratio	6,281.93x	7.57x
EV/Sales	5,042.14x	7.02x
EV/EBITDA	0.00x	0.00x
P/B Ratio	6.18x	1.85x
P/FCF Ratio	N/A	N/A
EV/FCF	-10.02x	-4.13x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	50.39x
Revenue & Growth
Revenue (TTM)	$0	$92M
Revenue Growth (YoY)	N/A	278712.1%
Forward Rev Growth	371.1%	40.6%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-208.8%
Net Margin (TTM)	0.0%	-194.7%
FCF Margin (TTM)	N/A	-169.9%
Net Income (TTM)	$-89M	$-179M
FCF (TTM)	$-57M	$-156M
EPS (TTM)	-$1.19	-$2.55
ROE (TTM)	-8938.0%	-4133.0%
ROA (TTM)	-5631.0%	-3590.0%
ROIC (TTM)	-6512.0%	-4087.0%
Financial Health
Cash	$202M	$70M
Debt	$48M	$20M
Net Cash/Debt	$154M	$51M
Current Ratio (TTM)	16.09x	8.03x
Quick Ratio (TTM)	15.89x	7.68x
Debt/Equity (TTM)	0.38x	0.05x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	-0.28	2.90
52W Performance	57.8%	38.0%
YTD Performance	82.7%	82.1%
% from 52W High	-29.0%	-21.3%
% from 52W Low	128.5%	91.5%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.18x
FCF Yield (TTM)	-7.9%	-22.4%
Earnings Yield (TTM)	-12.2%	-25.7%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	278,542.3
EV/GP/RG	N/A	N/A
Ticker research	View CADL research	View FDMT research